文献速递淋巴瘤

免疫化疗时代根据治疗强度分析80岁及以上弥漫大B细胞淋巴瘤患者的生存:一项瑞典淋巴瘤登记研究

Survival of very elderly patients with diffuse large B-cell lymphoma according to treatment intensity in the immunochemotherapy era: a Swedish Lymphoma Register study.
PubMed 文献 · Br J Haematol · 2020-05-12

这项基于瑞典登记数据的全国性人群研究纳入2007-2014年确诊的1194例年龄≥80岁弥漫大B细胞淋巴瘤患者,比较不同治疗强度及不同医疗区域间的生存。结果显示接受治愈性治疗者2年总生存54%、相对生存64%,优于低强度治疗(26%;33%)和姑息治疗(6%;7%),区域间治愈性治疗比例45%-76%,治愈性治疗比例低的区域生存显著较差(多变量风险比1.3,95%置信区间1.1-1.6)。

要点

  • 年龄≥80岁患者接受治愈性治疗2年总生存54%、相对生存64%,优于低强度治疗与姑息治疗。
  • 各医疗区域治愈性治疗比例45%-76%,比例低的区域生存显著较差(多变量风险比1.3,95%置信区间1.1-1.6)。
  • 治疗强度与区域同时纳入模型后区域不再独立,提示区域生存差异源于治疗差异。

核心结论

  • 年龄≥80岁的弥漫大B细胞淋巴瘤患者似乎可从以治愈为目的的利妥昔单抗联合蒽环类方案治疗中获益。

研究设计与样本

  • 基于瑞典登记数据的全国性、人群研究,纳入2007-2014年在瑞典确诊的1194例年龄≥80岁弥漫大B细胞淋巴瘤患者,收集临床特征、居住地、合并症、治疗与生存信息,并比较瑞典各医疗区域间的治疗差异及生存差异。

主要发现

  • 年龄≥80岁接受治愈性治疗者2年总生存54%、相对生存64%,低强度治疗者为26%和33%,姑息治疗者为6%和7%。
  • 各医疗区域接受治愈性治疗的患者比例在45%-76%之间。
  • 治愈性治疗患者比例低的区域生存显著较差,多变量风险比1.3(95%置信区间1.1-1.6)。
  • 治疗强度与区域同时纳入模型时区域不再独立,提示区域生存差异源于治疗差异。
  • 年龄校正的国际预后指数与生存独立相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diffuse large B-cell lymphoma (DLBCL) incidence rises with increasing age. Rituximab-anthracycline-based regimens offer a potential cure but also risks of adverse events, especially in the elderly. Using Swedish registers, we conducted a nationwide, population-based study of DLBCL in the very elderly. We obtained information on clinical characteristics, residence, comorbidity, therapy and survival for the 1194 patients aged ≥80 years diagnosed in Sweden 2007-2014. To address selection bias, we also investigated treatment differences between Sweden's Healthcare Regions and whether there were survival differences between the Regions. The 2-year overall and relative survivals were better in patients aged ≥80 years given treatment with curative intent (54%; 64%) than low-intensity (26%; 33%), or palliative treatment (6%; 7%). The fraction of patients treated with curative intent varied between the Healthcare Regions (45-76%). Survival was significantly inferior in Regions with few patients treated with curative intent (multivariable hazard ratio 1.3, 95% confidence interval 1.1-1.6). When treatment intensity and Regions competed, Regions were no longer independent, suggesting that Regional survival differences are due to therapeutic differences. Furthermore, we found that the age-adjusted International Prognostic Index was independently associated with survival. We conclude that patients aged ≥80 years with DLBCL appear to benefit from rituximab-anthracycline-based treatment given with curative intent.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Sonnevi K, Wästerlid T, Melén CM, et al. Survival of very elderly patients with diffuse large B-cell lymphoma according to treatment intensity in the immunochemotherapy era: a Swedish Lymphoma Register study. Br J Haematol. 2020. PMID: 32400004. doi:10.1111/bjh.16737

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。